Inactive Instrument

Allena Pharmaceuticals, Inc. Stock price

Equities

ALNA

US0181191075

Biotechnology & Medical Research

Dynamic Chart
Managers TitleAgeSince
Founder 71 11-06-23
Chief Operating Officer - 17-12-31
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Founder 71 11-06-23
Director/Board Member 61 21-04-05
Director/Board Member 66 20-10-04
More insiders
Allena Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. The Company is focused on metabolic disorders that result in excess accumulation of certain metabolites that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease (CKD) and end-stage renal disease (ESRD). The Company's lead product candidate, ALLN-346, is an orally administered, urate-degrading enzyme for patients with hyperuricemia and gout in the setting of advanced CKD. The Company is conducting two Phase IIa for ALLN-346. The Company's wholly owned subsidiaries include Allena Pharmaceuticals Security Corporation (Security Corporation) and Allena Pharmaceuticals Ireland Limited.
More about the company
  1. Stock
  2. Equities
  3. Stock Allena Pharmaceuticals, Inc. - OTC Markets